Literature DB >> 9449276

Treatment of histoplasmosis with MK-991 (L-743,872).

J R Graybill1, L K Najvar, E M Montalbo, F J Barchiesi, M F Luther, M G Rinaldi.   

Abstract

BALB/c nu/+ immunocompetent and athymic (nu/nu) mice were infected intravenously with yeast cells of Histoplasma capsulatum. Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts. MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9449276      PMCID： PMC105471     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis.

Authors:  G S Hall; C Myles; K J Pratt; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 2.  Amphotericin B: 30 years of clinical experience.

Authors:  H A Gallis; R H Drew; W W Pickard
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

3.  Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase.

Authors:  D Beaulieu; J Tang; D J Zeckner; T R Parr
Journal:  FEMS Microbiol Lett       Date:  1993-04-01       Impact factor: 2.742

Review 4.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

5.  Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.

Authors:  J Wheat; R Hafner; M Wulfsohn; P Spencer; K Squires; W Powderly; B Wong; M Rinaldi; M Saag; R Hamill; R Murphy; P Connolly-Stringfield; N Briggs; S Owens
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

6.  Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome.

Authors:  S Norris; J Wheat; D McKinsey; D Lancaster; B Katz; J Black; M Driks; R Baker; K Israel; D Traeger
Journal:  Am J Med       Date:  1994-06       Impact factor: 4.965

7.  Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice.

Authors:  G S Kobayashi; S J Travis; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

8.  Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review.

Authors:  E Anaissie; A Gokaslan; R Hachem; R Rubin; G Griffin; R Robinson; J Sobel; G Bodey
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

9.  Experimental chemotherapy of histoplasmosis in nude mice.

Authors:  D M Williams; J R Graybill; D J Drutz
Journal:  Am Rev Respir Dis       Date:  1979-10

10.  Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; D Krupa; V B Pikounis; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
View more
  16 in total

1.  Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model.

Authors:  G M González; R Tijerina; L K Najvar; R Bocanegra; M Luther; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Caspofungin: the first agent available in the echinocandin class of antifungals.

Authors:  Joseph Rybowicz; Cheryle Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-01

3.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India.

Authors:  Shallu Kathuria; Pradeep K Singh; Jacques F Meis; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum.

Authors:  Chadi A Hage; Patricia Connolly; Daniel Horan; Michelle Durkin; Melinda Smedema; Robert Zarnowski; Patricia Smith; L Joseph Wheat
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

6.  Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.

Authors:  S Kohler; L J Wheat; P Connolly; C Schnizlein-Bick; M Durkin; M Smedema; J Goldberg; E Brizendine
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  Caspofungin.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

Authors:  K V Clemons; M Martinez; L Calderon; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

Authors:  Ana Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum.

Authors:  Jessica A Edwards; Megan M Kemski; Chad A Rappleye
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.